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Background: Down syndrome is known to cause premature aging in several organ systems. 
However, it remains unclear whether this aging effect also affects the structure and function of 
the large arterial trunks. In this controlled study, the possibility of changes in the large arteries 
due to aging was evaluated in patients with Down syndrome.
Methods: Eighty-two subjects of both genders were selected. The Down syndrome group had 
41 active subjects consisting of 19 males and 22 females (mean age 21 ± 1, range 13–42 years) 
without cardiovascular complications and who did not use vasoactive drugs. The control group 
consisted of 41 healthy individuals without trisomy 21 of the same gender and age as the Down 
syndrome group and who did not use vasoactive medication. Carotid–femoral pulse wave velocity 
was obtained as an index of aortic stiffness using an automatic noninvasive method.
Results: Individuals with Down syndrome had significantly lower blood pressure than those 
in the control group. Systolic blood pressure for the Down syndrome group and control group 
was 106 ± 2 mmHg vs 117 ± 2 mmHg (P , 0.001), respectively; diastolic blood pressure was 
66 ± 2 mmHg vs 77 ± 2 mmHg (P , 0.001); and mean arterial pressure was 80 ± 1 mmHg vs 
90 ± 1 mmHg (P , 0.001). Only age and systolic blood pressure were shown to correlate 
significantly with pulse wave velocity, but the slopes of the linear regression curves of these 
two variables showed no significant difference between the two study groups. Pulse wave 
velocity, which was initially significantly lower in the Down syndrome group (7.51 ± 0.14 m/s vs 
7.84 ± 0.12 m/s; P , 0.05), was similar between the groups after systolic blood pressure adjust-
ment (7.62 ± 0.13 m/s vs 7.73 ± 0.13 m/s).
Conclusion: Despite evidence in the literature that patients with Down syndrome undergo 
early aging, this process does not seem to affect the large arterial trunks, given that values of 
carotid-femoral pulse wave velocity were similar in individuals with or without trisomy 21. 
Considering that Down syndrome presents with chronic hypotension, it is reasonable to pro-
pose that the prolonged reduction of arterial distending pressure may contribute to functional 
preservation of the arteries in patients with Down syndrome.
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Introduction
The role of the large arterial trunks in the genesis, perpetuation, and aggravation of 
cardiovascular disease is accentuated in certain population groups,1–3 and high arte-
rial stiffness has been described as an early marker of changes in arterial structure or 
asymptomatic atherosclerotic lesions.4,5
In recent years, there has been great interest in determining the effects of aging on 
the structure of the vascular system. Several mechanisms, including apoptosis6 and the 
telomeric hypothesis of cellular aging, have been proposed to influence such changes 
functionally or structurally.7,8 Studies also report that factors such as height, body mass 
index, and heart rate can influence the behavior of the large arteries.9–11 These changes Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
376
Rodrigues et al
are similar to those observed in systemic arterial hyperten-
sion, which can mimic the accelerated aging of large arteries 
when maintained at high levels.6,9,12,13
Evidence in the literature suggests that Down syndrome 
has an early aging component. Because it is a segmental 
progeroid syndrome in adults, Down syndrome displays 
a number of the characteristics seen in the normal aging 
population,14 and the quality of organ systems function is 
directly associated with functional aging.15,16
It is necessary to determine to what extent genetic 
disorders such as Down syndrome cause global biological– 
functional aging. The working hypothesis of this study 
was that individuals with Down syndrome could present 
with early structural and functional impairment of the 
large   arteries. The purpose of this study was to determine 
if individuals with Down syndrome show changes in aortic 
distensibility measured in vivo using noninvasive carotid–
femoral pulse wave velocity.
Methods
The ideal model for the study of biological aging would 
be to study patients with progeria, a condition that causes 
premature aging. In theory, if the number of beats in these 
individuals was essentially identical to the number of beats in 
a normal individual of the same age and there was increased 
aortic stiffness, a biological component could be implicated 
as a determinant of greater aortic rigidity. If aortic stiffness 
was identical in both groups, a hemodynamic component 
could be identified as a major determinant of aortic stiffness. 
However, the difficulty in finding individuals with progeria 
led our group to seek an alternative model, using individu-
als with trisomy 21 (Down syndrome), a population that is 
clearly progeroid and frequently described in the literature 
as a model for premature aging.17
In this study, 82 individuals of both genders were divided 
into two groups. One group consisted of 41 individuals with 
Down syndrome, aged 13–42 years. The control group con-
sisted of 41 healthy individuals matched for gender and age 
range. Individuals and their legal guardians were invited to 
participate voluntarily in this study. After being informed 
about all relevant procedures and aspects of the study, par-
ticipants signed an informed consent form in accordance with 
national and international standards for research conducted 
using human subjects. The study was approved by the Ethics 
in Human Research Committee of the Federal University of 
Espirito Santo.
A total of 41 individuals, comprising 22 females aged 
14–42 years and 19 males aged 13–35 years were preselected 
for the control group. All individuals performed their daily 
activities without cardiovascular symptoms, and none of 
them used vasoactive drugs or other medications that could 
influence the results of the study.
A total of 41 individuals with Down syndrome, compris-
ing 22 females aged 14–42 years and 19 males aged 13–35 
years were selected. All individuals performed their daily 
activities at the Pestalozzi and Association of Parents and 
Friends of Exceptional Children societies in Espirito Santo, 
Brazil, and had laboratory confirmation of simple trisomy 
of chromosome 21 in their medical records. None of the 
individuals had clinical evidence of cardiovascular disease 
or a history of vasoactive drug use.
All individuals underwent a general and specific clinical 
examination, including cardiologic auscultation, anthropo-
metric measurements (weight, height, waist, and hip) and 
recording of blood pressure. Conventional 12-lead electro-
cardiograms were performed, as well as echocardiograms to 
rule out any aortic valvulopathy or significant hemodynamic 
malformation. Echocardiography was performed using an 
ESAOTE® machine (Esaote Biomedica, Bologna, Italy) and 
color flow mapping equipped with printers. Subjects were 
examined in the left lateral position at approximately 45° by 
the same investigating cardiologist. Two patients with Down 
syndrome were replaced due to the finding of significant 
valvular lesions.
Weight (kg) and height (m) of the subjects in both groups 
were measured and recorded. Waist circumference at the 
umbilicus and hip height at the greater trochanter were also 
recorded. The waist–hip ratio was calculated as the waist 
circumference/hip circumference. Body mass index was 
calculated as weight (kg)/height (m2).
Systolic and diastolic blood pressures in both groups 
were taken three times using a standard mercury sphyg-
momanometer. Systolic pressure was determined as 
the moment when the first sound of Phase I Korotkoff 
appeared, and diastolic pressure was determined as the 
disappearance of sound at Phase V Korotkoff. Patients 
rested seated for 5–10 minutes before the measurements 
were taken. None had consumed alcohol, coffee, or food, 
or had smoked or performed exercise 30 minutes prior to 
blood pressure measurement. Three measurements were 
performed every 1–2 minutes with the patient seated and 
the arm supported at heart level. If any of the diastolic 
blood pressure measurements had differences . 5 mmHg, 
new measurements were taken until the differences were 
below this value. The average of three measurements was 
used. Mean arterial pressure was calculated as (2 × diastolic Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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blood   pressure) + systolic blood pressure/3. Heart rate was 
calculated from the electrocardiographic recording.
Aortic distensibility was measured using a noninvasive 
automatic device according to methods previously described 
by Asmar et al,18 which consists of the simultaneous acqui-
sition of digital acoustic signals in the carotid and femoral 
pulse and calculation of transit time. This methodology has 
been validated and was suitable for several reasons. Because 
easy wave registration is recorded at two points, the distance 
between these two points is large enough to allow for a safe 
calculation of the time interval between the two waves reg-
istered simultaneously on paper with a relatively high speed 
(150 mm/s). In addition, carotid–femoral pulse wave veloc-
ity reflects the elasticity of the aorta. Carotid–femoral pulse 
wave velocity is calculated by measuring the distance (m) 
traveled between two recording points and the transit time 
(s) between two simultaneous recording sites, ie, pulse wave 
velocity = distance carotid–femoral (m)/transit time (s).
Pulse wave velocity was obtained at 500 Hz using two 
pressure transducers (TY-396, Fukuda Denshi Co, Tokyo, 
Japan) placed on the common carotid and right femoral 
vein and connected to an automatic processor (Complior®, 
Colson AS, Paris, France). When a pulse wave of sufficient 
quality and gain was registered, an automatic calculation 
of the time delay between the two points was made. The 
distance (cm) between the two points was measured with a 
measuring tape. The average of five measurements of ten 
acquisitions was considered the pulse wave velocity for 
each individual.
statistical analysis
Sample size calculation was performed using Statmate® 
software (v 2.0; GraphPad, San Diego, CA), which showed 
n = 80, with an estimated ideal sample test power of 90% 
and alpha error of 0.05. To verify the differences between 
the average pulse wave velocity values of the two groups, 
a t-test was used for the two paired populations, as well as 
all other variables analyzed. Multivariate analysis and linear 
regression were performed to determine the main predictors 
of pulse wave velocity. Linear regression analyses between 
pulse wave velocity and systolic blood pressure and between 
pulse wave velocity and age were then used to evaluate the 
effects of systolic blood pressure and age on arterial stiffness. 
The slopes of the regression lines between systolic blood 
pressure and pulse wave velocity or age were compared using 
the t-test. The independent effects of systolic blood pressure 
and body mass index on pulse wave velocity were evaluated 
by analysis of covariance and adjusted. The new pulse wave 
velocity values for both groups after systolic blood pressure 
adjustment through analysis of covariance were compared. 
All results are shown as mean ± standard error of the mean 
(SEM). The significance level was set at P , 0.05.
Results
Table 1 shows the anthropometric and hemodynamic values 
for each group. With the exception of age and heart rate, 
there were significant differences (P , 0.05) between the 
studied variables (body mass index, systolic blood pressure, 
diastolic blood pressure, and waist–hip ratio) when compar-
ing the subjects with Down syndrome and the controls.
Multilinear regression between age, systolic blood 
pressure and body mass index (index maintained due to 
population studies performed by the MONICA/World Health 
Organization, project in Vitória, Brazil, showing a positive 
correlation with this variable) demonstrated that only age and 
systolic blood pressure were significantly (P , 0.05) related 
to pulse wave velocity, as shown in Table 2.
Figure 1 shows the linear regression models using 
Pearson’s correlation coefficient for age (Figure 1A), 
systolic blood pressure (Figure 1B), and carotid–femoral 
pulse wave velocity in the two groups. In the t-test for com-
parison between the linear regression curves, we found no 
significant differences in slope (b ± SEM) for pulse wave 
velocity and age (Figure 1A) between the groups (Down 
syndrome group 0.065 ± 0.019 m/s/year vs control group 
0.038 ± 0.018 m/s/year; P = 0.31, not significant) and or 
between pulse wave velocity and systolic blood pressure 
(Down syndrome group 0.033 ± 0.012 vs control group 
0.026 ± 0.012 mmHg, P = 0.68, not significant, Figure 1B). 
Table 1 Anthropometric and hemodynamic characteristics in the 
experimental groups
Down syndrome Controls P-value
Age (years) 21 ± 1 21 ± 1 –
Variance (13–42) (13–42)
Weight (kg) 55 ± 2 61 ± 2 ,0.05
Height (m) 1.47 ± 0.01 1.64 ± 0.01 ,0.001
BMi (kg/m2) 25 ± 1 22 ± 1 ,0.01
WHR 0.88 ± 0.01 0.80 ± 0.01 ,0.001
sBP (mmHg) 106 ± 2 117 ± 2 ,0.001
DBP (mmHg) 66 ± 2 77 ± 2 ,0.001
MAP (mmHg) 80 ± 1 90 ± 1 ,0.001
HR (bpm) 74 ± 2 76 ± 2 ns
PWV (m/s) 7.51 ± 0.14 7.84 ± 0.12 ,0.05
Note: Data are expressed as mean ± standard error.
Abbreviations: bpm, beats per minute; Ds, Down syndrome; BMi, body mass 
index; WHR, waist-hip ratio; sBP, systolic blood pressure; DBP, diastolic blood 
pressure; MAP, mean arterial pressure; HR, heart rate; PW, pulse wave velocity; 
NS, not significant.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Analysis of covariance showed a significant (P , 0.05) effect 
only for systolic blood pressure and pulse wave velocity, but 
this difference disappeared after systolic blood pressure was 
adjusted, as shown in Table 3.
Discussion
The most significant finding in this study was that individu-
als with Down syndrome do not have higher aortic stiffness 
values than individuals of the same age and gender without 
trisomy 21. All evidence described to date suggests that 
Down syndrome would be a good model for premature 
aging.14–16 However, some studies have found few athero-
sclerotic lesions and a low frequency of cardiovascular 
disease,19–21 small amounts of calcium in the arteries,22 and 
possible protection against development of atherosclerosis, 
due to increased antioxidant activity of superoxide dismutase 
in people with Down syndrome.23 Our study showed that 
carotid–femoral pulse wave velocity in these individuals 
was significantly lower than in a control group, but that after 
systolic blood pressure adjustment, the statistical significance 
of these values disappeared. This suggests that the accelerated 
aging described in other organ systems in Down syndrome 
does not occur in the aorta, confirming previous reports in 
the literature that indicate that the process of aging is accom-
panied by an increase in pulse wave velocity.24,25
Several theories have been proposed to explain aging, 
including random mutations in the DNA of somatic cells, 
cross-linking between collagen fibers and some proteins, 
cumulative tissue damage due to free radicals,26 and, more 
recently, the telomere hypothesis.27 However, no consensus 
has been achieved regarding our understanding of the aging 
process.
The search for mechanisms that lead to appropriate 
growth have dominated scientific research for a long time. 
However, there is limited knowledge about the aging process, 
which is a period that dominates most of the lifespan, and we 
still have no representative biomarkers of aging that enable 
us to define accurate physiological age in humans.28
Although the mechanisms are still debated, the mani-
festations of aging have been well described. Identification 
of early structural and hemodynamic changes with the aim 
of identifying factors that may trigger the process, slow it, 
and attenuate or block it when already in progress are still 
needed. Although a convention for characterizing arterial 
stiffness29 has not yet been established, arterial stiffness 
has been significantly correlated with aging. An increase in 
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Figure 1 Multivariate linear regression model with Pearson’s correlation coefficient 
between age, systolic blood pressure, and carotid–femoral pulse wave velocity in 
controls and subjects with Down syndrome.
Table 2 Multivariate linear regression with Pearson’s correlation 
of factors associated with carotid–femoral pulse wave velocity in 
controls and subjects with Down syndrome
Coefficient Correlation P-value
constant 2.937 – ,0.01
Age (years) 0.051 0.385 ,0.001
BMi (kg/m2) 0.012 0.076 ns
sBP (mmHg) 0.030 0.413 ,0.001
Abbreviations:  BMi,  body  mass  index;  sBP,  systolic  blood  pressure;  ns,  not 
significant.
Table 3   Analysis  of  covariance  between  carotid-femoral 
pulse  wave  velocity  values  in  controls  and  subjects  with 
Down syndrome before and after adjustment of systolic blood 
pressure
Down syndrome Control P-value
Age (years) 21 ± 1 21 ± 1 –
Variance (13–42) (13–42) –
PWV (m/s) 7.51 ± 0.14 7.84 ± 0.12 0.045
Adjusted PWV (m/s) 7.62 ± 0.13 7.73 ± 0.13 0.577
Abbreviation: PWV, pulse wave velocity.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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arterial stiffness can serve as an early marker of asymptom-
atic atherosclerotic lesions and/or structural changes due to 
hypertension.30 Studies using pulse wave velocity, a widely 
accepted index of arterial stiffness, have made the assess-
ment of arterial distensibility possible in various population 
groups and these have been compared with more invasive 
measures.18,31–34
In the general population, it is well established that aging 
is characterized by dilatation and progressive increase in 
stiffness of the large arteries, and that age and blood pressure 
are independent determinants of aging. However, there has 
been nothing published about the status of the large arteries 
in people with Down syndrome, who frequently present with 
segmented characteristics of premature aging, but now have 
an increased life expectancy.
In this study, we compared the anthropometric and 
hemodynamic characteristics of individuals having Down 
syndrome with those in age-matched and gender-matched 
individuals without trisomy 21. In addition, quantitative 
information about the large arteries of controls and subjects 
with Down syndrome was obtained by pulse wave velocity, 
as previously described by Asmar et al,18 and compared, 
enabling indirect evaluation of distensibility and arterial stiff-
ness. To avoid possible confounding influences due to gender 
and age, all individuals in the Down syndrome group were 
age-matched and gender-matched with the controls.9,12,35
In population studies, obesity has received special atten-
tion as an important risk factor for cardiovascular disease, 
where weight gain increases the risk in both men and women, 
and has been correlated with pulse wave velocity.36 Although 
obesity is not a consequence of Down syndrome,37 more than 
half of the children affected by this syndrome are overweight. 
The evidence for weight excess in our sample was suggested 
by body mass index and waist–hip ratio, and values for both 
variables were significantly greater than in the control group. 
The significantly higher weight in the control group might 
be explained by the mean greater stature of individuals 
not suffering from Down syndrome. In population studies 
(MONICA/World Health Organization project, Vitoria, 
Brazil), body mass index has been significantly correlated 
with pulse wave velocity, although this was not observed in 
our study, most likely due to the small sample size.
Aging is a determinant of vascular stiffening, and has 
been shown to be an independent predictor of pulse wave 
velocity.14,18,38 In our study, individuals were age-matched 
and gender-matched, and adjustments in this respect were 
not considered. Increases in pulse wave velocity in relation to 
age have been reported in all studies conducted so far. After 
linear regression analysis, this was also evident in our work, 
as shown in Figure 1A. To evaluate the effect of age on aortic 
stiffness in both groups, the slope of the regression curves 
for pulse wave velocity and age were compared, suggesting 
that age had a similar effect in both groups.
A close relationship has been demonstrated between 
pulse wave velocity and hemodynamic factors. Elevated 
cardiac frequency has been associated with higher pulse 
wave velocity and low arterial distension, and is a good 
predictor of cardiovascular morbidity.12,39 Cardiac frequency 
has been positively associated with several risk factors (eg, 
dyslipidemia, glycemia, physical inactivity) and arterial 
hypertension in particular.40 In our study, no significant 
difference in cardiac frequency was observed between the 
two groups. It is important to note that studies have shown 
deleterious effects of mechanical stress on the intimal layers 
of the arteries and that this can be offset by reducing cardiac 
frequency.11,31,38
Systemic hypertension has been associated with hyper-
trophy and hyperplasia of arterial smooth muscle as well as 
increased collagen synthesis, and has been acknowledged 
as one of the major risk factors for cardiovascular disease. 
Several studies have correlated congestive heart failure, 
stroke, chronic renal failure, and coronary disease with sys-
temic hypertension, and the need for its reduction is already 
a global consensus. Additionally, the literature has shown that 
hypertension seems to accelerate aging of the cardiovascular 
system due to decreased release of endothelial nitric oxide,28 
alterations in arterial wall composition, and decreased 
functional distensibility of the large arteries, all of which 
contribute to greater stress in the arterial wall.41
Systolic blood pressure values and age have been reported 
as the most important predictors of vascular aging in all the 
relevant studies reported to date. Our study showed that 
pulse wave velocity (Table 1) was significantly lower in 
the Down syndrome group before systolic blood pressure 
value adjustment. After adjustment, carotid–femoral pulse 
wave velocity between the two groups became similar and 
no longer statistically significant (Table 3 and Figure 1B). 
This finding confirms the importance of blood pressure as 
a determinant of arterial stiffness, generating a greater or 
lesser degree of hemodynamic stress. There is no evidence 
of premature aging of the arterial tree in subjects with Down 
syndrome of the same age and gender.
Systolic, diastolic, and mean arterial pressures were sig-
nificantly lower in patients with Down syndrome (Table 1). 
These data are consistent with studies performed by Richards 
and Enver42 who showed lower blood pressure in patients Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
380
Rodrigues et al
with Down syndrome in all age ranges from 5 years onwards, 
and are similar to those of Down syndrome patients with a 
mean age of 3.57 years in a study performed by Russo et al.43 
Other studies11,18,31,38 have shown a correlation between pulse 
wave velocity and systolic blood pressure, where higher 
blood pressure leads to greater pulse wave velocity and 
consequently greater arterial stiffness, as shown in the linear 
regression between carotid–femoral pulse wave velocity and 
systolic blood pressure for both groups evaluated in this 
study (Table 2). Analysis of the linear regression showed 
no significant difference in the effects of blood pressure on 
the mechanical properties of the vessels (Figure 1B), sug-
gesting an equal influence of this variable in both the Down 
syndrome and control groups.
Increased pulse wave velocity is associated with dilatation 
and stiffening of the large vessels, and these characteristics 
accompanied the aging process and the similar influence of 
age and systolic blood pressure on aortic stiffness in both 
groups. Our findings allow us to state that there is no evidence 
of premature aging of the arterial tree in patients with Down 
syndrome, a condition which can be described as a form of 
progeria. Our results suggest that systolic blood pressure is 
an independent predictor of pulse wave velocity and that 
individuals with Down syndrome show lower values than 
people without trisomy 21. This may have a lower impact on 
the endothelium of the blood vessels and result in a lower 
turnover of cells, thereby causing lower vascular telomere 
wear and contributing to slower aging of the system.
Despite all the issues raised in the literature involving 
premature aging of individuals with Down syndrome,14–16 
our results indicate that these individuals show no prema-
ture aging of their arterial vessels. It can be speculated that 
hypotension, a characteristic of this syndrome, attenuates the 
possible genetic effects that could contribute to accelerated 
aging of the vascular system. Although speculative, there is 
the possibility that maintaining low blood pressure levels 
may slow the aging process of the vascular system, which 
is the goal of any antihypertensive therapy.
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